Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/145039
Authors: 
Gamba, Simona
Year of Publication: 
2016
Series/Report no.: 
CESifo Working Paper 6004
Abstract: 
This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of 74 countries. The identification strategy exploits the different timing across countries of two sets of IPR reforms. Domestic innovation is measured as citation-weighted domestic patents filed at the European Patent Office (EPO): to account for their distribution, count data models are used. A Zero Inated Negative Binomial model is adopted to consider the choice not to patent at the EPO. Results show that, in the short-run, IPR stimulate innovation. The effect for developing countries is roughly half of that for developed countries.
Subjects: 
intellectual property rights
developing countries
pharmaceutical sector
innovation
patents
TRIPS
JEL: 
O34
O31
I18
K11
Document Type: 
Working Paper

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.